MX2023007869A - Compuestos que comprenden un ligando de proteina de activacion de fibroblasto y uso del mismo. - Google Patents

Compuestos que comprenden un ligando de proteina de activacion de fibroblasto y uso del mismo.

Info

Publication number
MX2023007869A
MX2023007869A MX2023007869A MX2023007869A MX2023007869A MX 2023007869 A MX2023007869 A MX 2023007869A MX 2023007869 A MX2023007869 A MX 2023007869A MX 2023007869 A MX2023007869 A MX 2023007869A MX 2023007869 A MX2023007869 A MX 2023007869A
Authority
MX
Mexico
Prior art keywords
compounds
activation protein
protein ligand
fibroblast activation
xaa1
Prior art date
Application number
MX2023007869A
Other languages
English (en)
Inventor
Frank Osterkamp
Ulrich Reineke
Christiane Smerling
Christian Haase
Matthias Paschke
Dirk Zboralski
Eberhard Schneider
Aileen Höhne
Jan Ungewiss
Anne Bredenbeck
Hacht Jan Lennart Von
Jessica Wahsner-Teschner
Original Assignee
3B Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3B Pharmaceuticals Gmbh filed Critical 3B Pharmaceuticals Gmbh
Publication of MX2023007869A publication Critical patent/MX2023007869A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8103—Exopeptidase (E.C. 3.4.11-19) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14001—Dipeptidyl-peptidase I (3.4.14.1), i.e. cathepsin-C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21026—Prolyl oligopeptidase (3.4.21.26), i.e. proline-specific endopeptidase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Optics & Photonics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un compuesto que comprende un péptido cíclico de la fórmula (I) (ver Fórmula) y un grupo A de modificación de N-terminal sujeto a Xaa1 en donde cada uno de Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, Xaa6 y Xaa7 es un residuo de un aminoácido, y Yc es una estructura de fórmula (X) (ver Fórmula).
MX2023007869A 2021-01-07 2022-01-07 Compuestos que comprenden un ligando de proteina de activacion de fibroblasto y uso del mismo. MX2023007869A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163134704P 2021-01-07 2021-01-07
PCT/EP2022/050280 WO2022148843A1 (en) 2021-01-07 2022-01-07 Compounds comprising a fibroblast activation protein ligand and use thereof

Publications (1)

Publication Number Publication Date
MX2023007869A true MX2023007869A (es) 2023-09-22

Family

ID=80050672

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007869A MX2023007869A (es) 2021-01-07 2022-01-07 Compuestos que comprenden un ligando de proteina de activacion de fibroblasto y uso del mismo.

Country Status (11)

Country Link
US (1) US20230212549A1 (es)
EP (1) EP4274835A1 (es)
JP (1) JP2024503637A (es)
KR (1) KR20230129261A (es)
CN (1) CN116940585A (es)
AU (1) AU2022205523A1 (es)
CA (1) CA3206863A1 (es)
CL (1) CL2023001991A1 (es)
IL (1) IL303925A (es)
MX (1) MX2023007869A (es)
WO (1) WO2022148843A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023152671A1 (en) 2022-02-09 2023-08-17 Novartis Ag Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
NZ503359A (en) 1997-09-29 2002-02-01 Point Therapeutics Inc Method for proliferating haematopoietic cells in vitro in the absence of exogenous cytokines
EP0953639A1 (en) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
AU2001256325A1 (en) 2000-03-17 2001-09-24 Boehringer Ingelheim Pharma Kg Human and humanized fap-alpha-specific antibodies
US7374898B2 (en) 2004-10-12 2008-05-20 The Research Foundation Of State University Of New York Peptide inhibitors against seprase
WO2006125227A2 (en) 2005-05-19 2006-11-23 Genentech, Inc. Fibroblast activation protein inhibitor compounds and methods
US8933201B2 (en) 2006-06-07 2015-01-13 The Board Of Regents Of The University Of Oklahoma Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use
JP2010523477A (ja) 2007-03-20 2010-07-15 トラスティーズ オブ タフツ カレッジ 線維芽細胞活性化タンパク質の阻害剤、およびそれを使用する方法
WO2010036814A1 (en) 2008-09-25 2010-04-01 Molecular Insight Pharmaceuticals, Inc. Selective seprase inhibitors
WO2011040972A1 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Anti-fibroblast activation protein antibodies and methods and uses thereof
BR112013003361B8 (pt) 2010-08-13 2022-01-25 Roche Glycart Ag Anticorpo, composição, conjugado de anticorpo,formulação farmacêutica e uso do anticorpo
WO2013107820A1 (en) 2012-01-17 2013-07-25 Universiteit Antwerpen Novel fap inhibitors
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
GB201402006D0 (en) 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
WO2016146174A1 (en) 2015-03-17 2016-09-22 Biontech Ag Compositions and methods for diagnosis and treatment of cancer
CN109689115A (zh) 2016-06-10 2019-04-26 拜耳制药股份公司 放射性药物配合物
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
EA202090776A1 (ru) 2017-10-23 2020-07-27 Дзе Джонс Хопкинс Юниверсити Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha)
EP3763726A1 (en) * 2019-07-08 2021-01-13 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof

Also Published As

Publication number Publication date
CN116940585A (zh) 2023-10-24
JP2024503637A (ja) 2024-01-26
CA3206863A1 (en) 2022-07-14
WO2022148843A1 (en) 2022-07-14
US20230212549A1 (en) 2023-07-06
KR20230129261A (ko) 2023-09-07
AU2022205523A1 (en) 2023-07-13
IL303925A (en) 2023-08-01
EP4274835A1 (en) 2023-11-15
CL2023001991A1 (es) 2023-12-15

Similar Documents

Publication Publication Date Title
MX2022000251A (es) Compuestos que comprenden un ligando de proteina de activacion de fibroblasto y uso del mismo.
AU4837300A (en) Antimicrobial theta defensins and methods of using same
MX2023007869A (es) Compuestos que comprenden un ligando de proteina de activacion de fibroblasto y uso del mismo.
MX2015011243A (es) Peptidos para su uso en el tratamiento topico de enfermedades neurodegenerativas retinianas, en particular en fases de tempranas de retinopatia diabetica y otras enfermedades retinianas en las cuales la neurodegeneracion desempeña una funcion esencial.
CO6150201A2 (es) Anticuerpo humanizado contra beta amiloide
CA2651990C (en) Improved antimicrobial peptides
HK1088613A1 (en) Peptide inhibitors of toxins derived from ll-37
AU2014247189B2 (en) Beta-hairpin peptidomimetics
CA2453112A1 (en) New cationic peptides of the dermaseptin family isolated from the skin secretion of phyllomedusa hypochondrialls
Yoshida et al. New insight into the mode of action of vancomycin dimers in bacterial cell wall synthesis
US20180072775A1 (en) Beta-Hairpin Peptidomimetics
WO2006108686A3 (en) Bnp agonists
EP0821003A4 (en) Peptides and medicinal products containing them for autoimmune diseases
AU2003264679A8 (en) Peptides having antimicrobial properties and compositions containing same in particular for preserving foods
US11753446B2 (en) Beta-hairpin peptidomimetics
EP3201218B1 (en) Beta-hairpin peptidomimetics
ATE465172T1 (de) Peptidträger für die verabreichung von arzneimitteln
BR112015018283A2 (pt) Composto peptídico agonista e composição farmacêutica ou veterinária
PE20030493A1 (es) Hepta-,octa-,y nonapeptidos con actividad antiangiogenica
WO2008114577A2 (ja) 抗菌性ペプチド
MX2023007406A (es) Composiciones que comprenden ciclotidos y otros peptidos insecticidas y usos de las mismas.
WO2019091601A1 (en) Beta-hairpin peptidomimetics
PE20030693A1 (es) Tetra-,penta-,hexa- y heptapeptidos con actividad antiangiogenica
TH146646A (th) วิธีการสำหรับการเพิ่มชีวมวลพืช